Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
- Takeda Considering Manufacturing Plant Move on Power Shortage: Keizai Doyukai Chairman Hasegawa
April 5, 2012
- Nihon Chouzai to Soon Conclude Memorandum with Wholesalers for Provisional Prices
April 5, 2012
- Pharmacists Expect Increase in Use of Amlodipine Generics: Survey
April 5, 2012
- GSK Applies for Fixed-Dose Combination Tablet for Treatment/Prevention of Malaria
April 5, 2012
- Shionogi Sees Positive Results of PIII Study for Anti-HIV Drug
April 5, 2012
- Ajinomoto Pharmaceuticals Obtains Rights to Develop, Commercialize CC Treatment in Japan, Asia
April 5, 2012
- Ajinomoto Pharmaceuticals Ties Up with DKSH Group in Vietnam
April 5, 2012
- Novartis Draws Up Guidelines for MRs on How to Cope in Times of Disaster
April 4, 2012
- Sogo Rinsho HD to Establish New Subsidiary for Full-Scale Market Entry of CRO Business
April 4, 2012
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…